## **REMARKS**

I. Application Status. The present Amendment is filed concurrently with an Request for Continued Examination (RCE) and an Information Disclosure Statement. The filing of the RCE terminates the appeal that was pending in the application.

II. Status of the Claims. New claims 73-76 have been added. The new claims are drawn to a method for lowering triglycerides in a patient in need thereof. Support for the new claims is found throughout the specification, e.g., at page 4, lines 11-20, page 12, lines, 12-19 and page 40, lines 19-32. By this Amendment, no new matter has been added to the application.

Upon entry of this Amendment, claims 26-29 and 36-76 are pending.

III. Request for Reconsideration. Reconsideration of claims 26-29 and 36-72 is requested in view of the arguments set forth in Applicant's Appeal Brief filed on January 3, 2005 and Applicant's Reply Brief filed June 6, 2005. Both aforementioned Briefs are incorporated herein by reference.

IV. New claims. New claims 73-76 are directed to a method of lowering triglycerides in a patient in need thereof. New claims 73-76 are patentable for at least the reasons set forth in Applicant's aforementioned Appeal and Reply Briefs. The prior art of record fails to disclose or suggest the claimed method of lowering triglycerides set forth in claims 73-76. Hence, the new claims are novel and non-obvious over the prior art of record. Claims 73-76 further comply with all requirements set forth in sections 101 and 112. Allowance of new claims 73-76 is requested, accordingly.

## **CONCLUSION**

A prompt and favorable action is earnestly requested. If the Examiner believes prosecution of the application could be advanced by an Examiner's Amendment or an interview, the

Docket No.: 6169.200-US

Application No.: 09/800,541

Examiner is respectfully invited to telephone Applicant's attorney listed below, at the Examiner's convenience.

9

Dated: April 13, 2006

Respectfully submitted,

By Mitchell Bernstein, Reg. No. 46,550 For Richard W. Bork

Registration No.: 36,459

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540

(609) 987-5800